Evolving therapeutics in colorectal cancer peritoneal metastases.
2/5 보강
OpenAlex 토픽 ·
Intraperitoneal and Appendiceal Malignancies
Nanoplatforms for cancer theranostics
Occupational and environmental lung diseases
Colorectal cancer peritoneal metastases (CRC-PM) are highly aggressive and present distinct therapeutic challenges.
APA
Justin M Bader, Nicole Aguirre, et al. (2026). Evolving therapeutics in colorectal cancer peritoneal metastases.. Cancer metastasis reviews, 45(2). https://doi.org/10.1007/s10555-026-10335-0
MLA
Justin M Bader, et al.. "Evolving therapeutics in colorectal cancer peritoneal metastases.." Cancer metastasis reviews, vol. 45, no. 2, 2026.
PMID
42024175
Abstract
Colorectal cancer peritoneal metastases (CRC-PM) are highly aggressive and present distinct therapeutic challenges. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have emerged as potential therapeutic approaches, but their roles remain controversial following recent clinical trials. This review summarizes the evolving landscape of CRC-PM management, including diagnostic challenges, conflicting views of CRS and HIPEC, systemic therapies and new treatment approaches, overview of recent and ongoing landmark clinical trials, and discussion of variations in societal and global guideline recommendations.